Clinical trials: Glaucoma Open-angle
- Condition Glaucoma Open-angle
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Open-Angle Glaucoma
A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma
The goal of this study is to learn about outcomes after bio-reinforced canaloplasty surgery in patients with OAG. The key question the study aims to answer is: How much does the surgical procedure lower pressure inside the eye…
- Trial name
- BOOST (NCT07520175)
- Testing
- AlloSpan Canal Platform Bio-Reinforced Canaloplasty
- Where
- 9 sites in United States
- Volunteers
- 300 people
- Sponsor
- Iantrek, Inc.
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free [PF], fixed-dose combination [FDC] investigational product (IP) in subjects with open-angle…
- Trial name
- Firecrest (NCT07354516)
- Testing
- QLS-111-FDC, Latanoprost (0.005%)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Qlaris Bio, Inc.
Open-angle Glaucoma (OAG)
5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
This study is designed to collect clinical data at 3, 4, and 5 years postoperatively for participants who completed the CREST Study without having secondary IOP-lowering surgery in the study eye(s).
- Trial name
- CREST-XT (NCT07480343)
- Testing
- CycloPen Micro-Interventional Cyclodialysis System, CycloPen Micro-Interventional Cyclodialysis System Post Cataract
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Iantrek, Inc.
Open Angle Glaucoma, Intraocular Pressure
An Extension Trial for Patients With Open-Angle Glaucoma Who Participated in the DF6-CL-20-01 Protocol.
The purpose of this study is to evaluate long term safety and effectiveness of the STREAMLINE® SURGICAL SYSTEM
- Trial name
- NCT06230393
- Testing
- STREAMLINE® SURGICAL SYSTEM
- Where
- Costa Rica
- Volunteers
- 17 people
- Sponsor
- New World Medical, Inc.
Glaucoma, Open-Angle
An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)
The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in…
- Trial name
- NCT04872348
- Testing
- OMNI® Surgical System
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Sight Sciences, Inc.
Open-angle Glaucoma
Expanded Access to Bimatoprost (Durysta)
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Durysta (Bimatoprost) prior to approval by the local regulatory agency.
- Trial name
- NCT05338606
- Testing
- Bimatoprost Sustained Release Implant
- Sponsor
- AbbVie
Glaucoma, Open-Angle
A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
The purpose of this study is to evaluate the long-term safety and effectiveness of the OMNI® Surgical System in subjects who were treated under protocol #06213
- Trial name
- NCT05044793
- Testing
- OMNI® Surgical System
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Sight Sciences, Inc.
Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.
- Conditions
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
- Trial name
- NCT06249152
- Testing
- QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Qlaris Bio, Inc.
Open Angle Glaucoma, Ocular Hypertension
Evaluation of Safety and Efficacy of PDP-716
The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.
- Trial name
- NCT03450629
- Testing
- Brimonidine Tartrate Ophthalmic Suspension, Brimonidine Tartrate Ophthalmic Solution
- Where
- 47 sites in United States
- Volunteers
- 682 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Glaucoma, Open-Angle
iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study
Long term follow up of subjects in the IDE study for iStent Inject to monitor safety
- Trial name
- NCT04624685
- Where
- 24 sites in United States
- Volunteers
- 475 people
- Sponsor
- Glaukos Corporation
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice.
- Trial name
- NCT01853085
- Testing
- Bimatoprost Ophthalmic Solution
- Where
- Germany
- Volunteers
- 1,830 people
- Sponsor
- Allergan
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical…
- Trial name
- NCT01999348
- Testing
- Fixed Combination Bimatoprost and Timolol
- Where
- Germany
- Volunteers
- 1,553 people
- Sponsor
- Allergan
Ocular Hypertension, Open-angle Glaucoma
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
- Trial name
- Rocket-1 (NCT02207491)
- Testing
- Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Aerie Pharmaceuticals
Ocular Hypertension, Open-angle Glaucoma
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution
- Trial name
- NCT02207621
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02% BID
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- Aerie Pharmaceuticals
Primary Open-angle Glaucoma
Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry
The purpose of this study is to observe the safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery in subjects with mild to moderate open-angle glaucoma.
- Trial name
- NCT01841437
- Testing
- iStent
- Where
- 18 sites in United States
- Volunteers
- 191 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma (OAG)
CyPass Clinical Experience Study
This study is to evaluate the long-term safety, effectiveness and clinical experience of the CyPass Micro-Stent in patients with glaucoma.
- Trial name
- CyCLE (NCT01097174)
- Testing
- CyPass Micro-Stent
- Where
- 14 sites in Austria, Bulgaria and 4 more
- Volunteers
- 555 people
- Sponsor
- Transcend Medical, Inc.
Primary Open Angle Glaucoma
Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort
The purpose of this study is to assess the long-term safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100R/L in subjects previously enrolled in Glaukos Study GC-003.
- Trial name
- NCT01836042
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.
- Trial name
- APOTUS (NCT02003534)
- Testing
- 0.15% Brimonidine Tartrate
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUSDI (NCT02020512)
- Testing
- 0.03% Bimatoprost
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to…
- Trial name
- NCT01589510
- Testing
- bimatoprost 0.01% ophthalmic solution
- Where
- Austria
- Volunteers
- 419 people
- Sponsor
- Allergan